← Back to Search

Heart Health Assessment Tool for Endometrial Cancer Survivors

N/A
Waitlist Available
Led By Kathryn E Weaver, PhD, MPH
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve heart health for cancer patients by asking them to use an electronic tool. Researchers hope to learn how to better help patients manage their heart health. #HeartHealth #CancerCare

Who is the study for?
This trial is for endometrial cancer survivors who are at least 18 years old, can read medical information in English, have an email address, and are more than 3 months post-cancer treatment. They should be scheduled for a routine check-up but not currently receiving cancer treatments or expected to live less than six months.
What is being tested?
The study tests a digital tool called the PREVENT Cardiovascular Health Assessment Tool along with surveys and interviews about heart health. It aims to understand how this tool might help manage heart health for cancer survivors outside of clinical settings.
What are the potential side effects?
Since this trial involves using an assessment tool and providing feedback rather than testing a drug or medical procedure, there are no direct physical side effects associated with participating in this study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants to Complete Heart Health Assessment - Feasibility
Secondary study objectives
Number of Participants Stating Satisfaction with PREVENT Tool
Number of Participants to Report Initiating Discussions Regarding Cardiovascular Health with Health Care Providers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PREVENT - Cardiovascular Health Assessment ToolExperimental Treatment3 Interventions
An adapted version of the PREVENT tool for endometrial cancer survivors will be used collect data during routine follow-up care for endometrial cancer that will yield a cardiovascular health score based on the Simple 7 risk factors (current smoking habits, body mass index, physical activity, diet, cholesterol, blood pressure and fasting plasma glucose).

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,403 Previous Clinical Trials
2,478,293 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,538 Total Patients Enrolled
Kathryn E Weaver, PhD, MPHPrincipal InvestigatorWake Forest Baptist Comprehensive Cancer Center

Media Library

PREVENT - Cardiovascular Health Assessment Tool Clinical Trial Eligibility Overview. Trial Name: NCT05796518 — N/A
Survivorship Research Study Groups: PREVENT - Cardiovascular Health Assessment Tool
Survivorship Clinical Trial 2023: PREVENT - Cardiovascular Health Assessment Tool Highlights & Side Effects. Trial Name: NCT05796518 — N/A
PREVENT - Cardiovascular Health Assessment Tool 2023 Treatment Timeline for Medical Study. Trial Name: NCT05796518 — N/A
~19 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top